Bora Pharmaceuticals joins hands with TaiRX, a Taiwan-based company focused on drug development, to formulate CVM-1118, an anticancer drug. TaiRX has developed CVM-1118, a medicine seen as a potential option for cancer. CVM-1118 is a tiny molecule chemical entity that has demonstrated anticancer activity in human cells while also having a high safety margin. As a part of its 5-year action plan, Bora Pharmaceuticals has reported to acquire a $100 million biologics site in Taiwan. With the help of the investment, Bora Pharmaceuticals is able to dramatically increase its biologics capabilities, giving its clients access to top-notch production facilities for their cutting-edge and novel pharmaceutical products.
Read More from ContractPharma
English